Mesoblast Ltd - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Mesoblast Ltd Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Mesoblast Ltd. The Group's principal activity is developing biological products in the field of regenerative medicine. It is developing an adult stem cell platform for use in the global orthopedic industry, targeting a range of bone, cartilage and musculoskeletal conditions. The Group has the worldwide exclusive rights for orthopedic indications relating to a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction, and culture of adult Mesenchymal Precursor Cells (MPCs). The Group holds a substantial interest in Angioblast Systems Inc., an American company developing the same platform technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report